{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:01:46Z","timestamp":1769342506344,"version":"3.49.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.2169\/internalmedicine.3220-19","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T22:03:02Z","timestamp":1563746582000},"page":"3449-3453","source":"Crossref","is-referenced-by-count":6,"title":["Myeloid\/Lymphoid Neoplasm with <i>PDGFRB<\/i> Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the <i>CCDC6-PDGFRB<\/i> Fusion Gene"],"prefix":"10.2169","volume":"58","author":[{"given":"Miki","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Hematology, International University of Health and Welfare, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, JCHO Funabashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, JCHO Funabashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagisa","family":"Oshima-Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shokichi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shio","family":"Mitsukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Iseki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoharu","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, JCHO Funabashi Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951, 2009.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127: 2391-2405, 2016.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"3","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","volume":"24","author":"M Bousquet","year":"2005","unstructured":"3. Bousquet M, Quelen C, De Mas V, et al. The t (8;9) (p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24: 7248-7252, 2005.","journal-title":"Oncogene","ISSN":"https:\/\/id.crossref.org\/issn\/0950-9232","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Reiter A, Walz C, Watmore A, et al. The t (8;9) (p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65: 2662-2667, 2005.","DOI":"10.1158\/0008-5472.CAN-04-4263"},{"key":"5","unstructured":"5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. World Health Organization, 2017."},{"key":"6","unstructured":"6. Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92: 1243-1259, 2017."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214, 2003.","DOI":"10.1056\/NEJMoa025217"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879-2891, 2004.","DOI":"10.1182\/blood-2003-06-1824"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481-487, 2002.","DOI":"10.1056\/NEJMoa020150"},{"key":"10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"10. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood 129: 704-714, 2017.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109: 61-64, 2007.","DOI":"10.1182\/blood-2006-05-024828"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 77: 307-316, 1994.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"13","unstructured":"13. Siena S, Sammarelli G, Grimoldi MG, et al. New reciprocal translocation t (5;10) (q33;q22) associated with atypical chronic myeloid leukemia. Haematologica 84: 369-372, 1999."},{"key":"14","unstructured":"14. Kulkarni S, Heath C, Parker S, et al. Fusion of H4\/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t (5;10) (q33;q21). Cancer Res 60: 3592-3598, 2000."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Garcia JL, Font de Mora J, Hernandez JM, et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 102: 2699-2700, 2003.","DOI":"10.1182\/blood-2003-05-1579"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Drechsler M, Hildebrandt B, Kundgen A, Germing U, Royer-Pokora B. Fusion of H4\/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 86: 353-354, 2007.","DOI":"10.1007\/s00277-006-0247-5"},{"key":"17","unstructured":"17. Bastie JN, Garcia I, Terre C, Cross NC, Mahon FX, Castaigne S. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica 89: 1263-1264, 2004."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Schwaller J, Anastasiadou E, Cain D, et al. H4 (D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t (5;10) (q33;q22). Blood 97: 3910-3918, 2001.","DOI":"10.1182\/blood.V97.12.3910"},{"key":"19","unstructured":"19. Alimena G, Breccia M, Mancini M, et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 18: 361-362, 2004."},{"key":"20","first-page":"1566","volume":"91","author":"M Breccia","year":"2006","unstructured":"20. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 91: 1566-1568, 2006.","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2402556","volume":"16","author":"NC Cross","year":"2002","unstructured":"21. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16: 1207-1212, 2002.","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/23\/58_3220-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T09:09:26Z","timestamp":1664010566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/23\/58_3220-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":21,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3220-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}